erdafitinib
Ligand Summary
Erdafitinib inhibited FGFR phosphorylation and signaling and decreased cell viability in cell lines expressing FGFR genetic alterations, including point mutations, amplifications, and fusions. Erdafitinib demonstrated antitumor activity in FGFR-expressing cell lines and xenograft models derived from tumor types, including bladder cancer.
UNII: 890E37NHMV
PubChem: 67462786
Guide to Pharmacology: 9039
ChEMBL: CHEMBL3545376
DrugCentral: 5327
LyCHI: YQ15HNNJQ6JG
Target Activities
31 Activities
Items per page:
10
1 – 10 of 31
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||